Psoriasis Treatment Market Analysis & Forecast: 2026-2033
The Psoriasis Treatment Market is estimated to be valued at USD 34.2 Bn in 2026 and is expected to reach USD 71.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.1% from 2026 to 2033.
The Psoriasis Treatment Market provides specialized therapeutic interventions for patients suffering from chronic autoimmune skin conditions. The market includes a broad spectrum of care ranging from first-line topical corticosteroids and vitamin D analogues to advanced biologics such as interleukin and TNF alpha inhibitors and emerging oral small molecules like TYK2 and PDE4 inhibitors.
The prevalence of chronic inflammatory skin diseases is increasing globally, thus creating a greater demand for targeted therapies among both pediatric and adult populations. Dermatologists and healthcare providers recognize the importance of early intervention and long-term disease control for improving patient quality of life and managing systemic comorbidities like psoriatic arthritis. Medical regulatory bodies now emphasize high skin clearance benchmarks and patient-reported outcomes, which makes advanced biologics and biosimilars a preferred standard for moderate to severe cases.
|
Current Event |
Description and the Impact |
|
Regulatory Approvals and Reimbursements in Key Regions
|
|
|
Advances in Precision Medicine and Biotechnology |
|
|
Public Awareness and Patient Advocacy Movements |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of therapy type, the biologics segment contributes the highest share of 49.60% in 2026 of the market. This is due to the clinical efficacy and sustained response rates these treatments provide as compared to traditional systemic options. By targeting specific pathways of the immune system, such as interleukin inhibitors and tumor necrosis factor blockers, biologics provide a level of precision that significantly improves skin clearance for patients with moderate to severe psoriasis. Dermatologists are favoring these therapies because they provide a more predictable long-term safety profile, which reduces the cumulative toxicity often associated with older oral medications.
Moreover, the shift toward biologics is bolstered by the rising availability of biosimilars, which has increased patient access by making high-tier treatment more economically viable for healthcare systems. The move toward patient centric care has also fueled this preference because biologics often require less frequent dosing to improve treatment adherence and overall quality of life.
For instance, in In February 2025, Biocon Biologics Ltd. (BBL), a global biosimilars firm under Biocon Ltd. announced the commercial availability of YESINTEK™ (ustekinumab-kfce) for US patients. It ranks among the first biosimilar to Stelara® (ustekinumab) in the country. YESINTEK helps treat Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This gives patients access to cheaper options for common long term autoimmune diseases.
In terms of distribution channel, the hospital pharmacies segment contributes the highest share of 42.20% in 2026 of the market due to their role as central locations for the administration of high-cost systemic and biologic drugs. The cutting-edge psoriasis drugs often require special storage conditions, making hospitals the most suitable locations for their management. The moderate to severe psoriasis patient will have access to intravenous infusions at this location where they will be monitored by specialists in real time for any potential side effects. This setup enhances safety compared to homecare alternatives.
Moreover, the hospital pharmacies play a crucial role in navigating the complexities of the reimbursement process for specialty drugs. A diverse team of pharmacy professionals collaborates with healthcare practitioners to manage prior authorization for patients facing high costs. By providing comprehensive diagnostic facilities alongside pharmaceutical services, these pharmacies provide patients an integrated treatment program that supports long term disease control.
To learn more about this report, Download Free Sample
North America has remained the dominant region with 44.70% in 2026 of the global Psoriasis Treatment Market over the past decade. The growth is owing to its sophisticated healthcare infrastructure and the high prevalence of autoimmune skin disorders among the population. The market growth is driven by the rapid adoption of cutting-edge biologic therapies such as interleukin inhibitors, which provide superior efficacy for moderate to severe cases.
The favorable reimbursement policies and heavy expenditure in research and development by major pharmaceutical firms have streamlined the introduction of innovative treatments. The expansion of the biosimilar landscape is also improving patient access to affordable care options while maintaining high safety standards. Furthermore, the rise of personalized medicine and digital health interaction allows for more precise disease management and improved patient compliance across the US and Canada.
For instance, in In March 2025, Fresenius Kabi, a subsidiary of Fresenius, and Formycon AG, a leading provider of quality biosimilars, announced the availability of Otulfi® (ustekinumab-aauz) in the US. Developed by Formycon AG, Otulfi® is a ustekinumab biosimilar to Stelara®. It treats moderate to severe Crohns disease and ulcerative colitis in adults, plus moderate to severe plaque psoriasis in adults.
Asia Pacific is rapidly becoming the fastest growing market for psoriasis treatment, owing to the increasing patient population and improving healthcare infrastructure in emerging economies. The countries of China, India, and Japan are the major contributors to this expansion. This is owing to their high spending and rising use of modern biological therapies. The market also witnessed growth due to the entry of cost-effective biosimilars, which provide affordable alternatives for a large and diverse demographic.
The growing public awareness campaigns and the implementation of digital health platforms are facilitating earlier diagnosis and more consistent disease management. These advancements, along with the region’s robust pharmaceutical manufacturing capabilities, are positioning the Asia Pacific region as a critical global hub for innovation in autoimmune skin disorder treatments.
For instance, in In May 2025, Biocon Biologics Ltd, a leading biosimilars company under Biocon Ltd, made an announcement that its partner Yoshindo Inc. launched Ustekinumab BS Subcutaneous Injection [YD] in Japan. It a biosimilar to Stelara® (ustekinumab), made by Biocon Biologics. It is sold and marketed by Yoshindo Inc.
In the U.S., the market is defined by its maturity, early access to cutting-edge medical breakthroughs, and a strong preference for targeted biological therapies. Recent trends show a significant move toward oral small molecules and next-generation inhibitors that offer patients high levels of skin clearance with the convenience of a pill or less frequent injections. The landscape is also shaped by the widespread entry of biosimilars, which provide more affordable alternatives as patents for major drugs expire. Additionally, there is a growing emphasis on personalized medicine and patient monitoring apps, which help clinicians tailor long-term management strategies for individuals with chronic moderate to severe cases.
For instance, in In February 2024, Teva Pharmaceuticals, a U.S. arm of Teva Pharmaceutical Industries Ltd., and Alvotech announced the availability of SELARSDI™ injection in the U.S. This biosimilar to Stelara® treats psoriatic arthritis, plaque psoriasis, Crohns disease, ulcerative colitis, child plaque psoriasis and child psoriatic arthritis.
China Psoriasis Treatment Market Trends
The China market is rapidly evolving from a traditional reliance on topical creams and light therapy toward a modern landscape led by cutting-edge systemic treatments. This shift is primarily fueled by the strategic inclusion of several high-efficacy biological agents in the National Reimbursement Drug List, which has made these inexpensive medications accessible to a much broader segment of the population. Furthermore, domestic pharmaceutical innovation is rising, with local companies successfully developing novel small molecules and biosimilars that compete directly with established global brands. As healthcare infrastructure continues to expand in smaller cities and rural areas, the rate of diagnosis is climbing, establishing China as one of the most dynamic regions for dermatological growth.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 34.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.1% | 2033 Value Projection: | USD 71.5 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The psoriasis treatment market is growing worldwide due to the number of people affected by this autoimmune disorder continually rising worldwide. This can be attributed mainly to environmental factors, increasing stress, and changes in food patterns that induce greater skin inflammation, thereby triggering this condition. As public awareness grows and diagnostic techniques become more sophisticated, healthcare providers are identifying patients earlier and more accurately than in previous decades. The prevalence of other disorders like obesity and metabolic syndrome is directly linked to the onset of chronic plaque psoriasis, thereby resulting in a larger population of affected individuals.
The growing population of affected individuals has created a massive demand for more effective and convenient therapeutic options. In repose, the pharmaceutical firms are working to develop more advanced treatments, from topical treatments to highly sophisticated systemic treatments. The shift toward personalized medicine is also gaining momentum as patients seek targeted solutions that provide long-term remission with fewer side effects. As a result, the continual stream of new patents entering the market ensures a strong pipeline of innovation.
For instance, in April 2025, Sun Pharma Sun Pharma teamed up with singer, Art Garfunkel an ILUMYA® patient and Rolling Stone's list of top 100 singers. Famous from Simon & Garfunkel, Art Garfunkel, hares his story of living with moderate to severe plaque psoriasis for the first time. The "I LUV YA for The Long Haul" campaign highlights the emotional side of psoriasis and helps others find good treatment.
Definition: The Psoriasis Treatment Market covers systemic and topical therapies such as specialized biologics, oral small molecules, and advanced topical formulations for various forms of the disease affecting the skin and joints. These solutions are commonly utilized by dermatologists for patients experiencing moderate to severe symptoms, thus addressing the underlying immune response instead of merely treating surface inflammation. Modern therapeutic approaches effectively reduce flare frequency, diminish skin plaques, and lower systemic inflammation, while also enhancing overall patient well-being and achieving better long-term health outcomes. Demand primarily comes from a growing aging population, dermatology clinics, hospitals, and specialty pharmacies facing rising autoimmune cases and preferences for long-term disease management.
Share
Share
About Author
Nikhilesh Ravindra Patel is a Senior Consultant with over 8 years of consulting experience. He excels in market estimations, market insights, and identifying trends and opportunities. His deep understanding of the market dynamics and ability to pinpoint growth areas make him an invaluable asset in guiding clients toward informed business decisions. He plays a instrumental role in providing market intelligence, business intelligence, and competitive intelligence services through the reports.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
